These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 18408493)

  • 1. The cost of vision for vitreoretinal interventions.
    Smiddy WE
    Curr Opin Ophthalmol; 2008 May; 19(3):195-201. PubMed ID: 18408493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The comparative effectiveness and cost-effectiveness of vitreoretinal interventions.
    Brown MM; Brown GC; Brown HC; Irwin B; Brown KS
    Curr Opin Ophthalmol; 2008 May; 19(3):202-7. PubMed ID: 18408494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
    Fletcher EC; Lade RJ; Adewoyin T; Chong NV
    Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of treatment of age-related macular degeneration: a review.
    Kymes Steven M
    Minerva Med; 2009 Feb; 100(1):69-78. PubMed ID: 19277005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic implications of current age-related macular degeneration treatments.
    Smiddy WE
    Ophthalmology; 2009 Mar; 116(3):481-7. PubMed ID: 19157562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on utilities and cost-utility analyses.
    Hollands H; Sharma S
    Curr Opin Ophthalmol; 2006 Jun; 17(3):223-7. PubMed ID: 16794433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of neovascular age-related macular degeneration: past, present and future directions.
    Smith BT; Joseph DP; Grand MG
    Curr Opin Ophthalmol; 2007 May; 18(3):240-4. PubMed ID: 17435433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomics and macular degeneration.
    Brown GC; Brown MM; Brown H; Godshalk AN
    Curr Opin Ophthalmol; 2007 May; 18(3):206-11. PubMed ID: 17435427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life and health economic assessments of age-related macular degeneration.
    Covert D; Berdeaux G; Mitchell J; Bradley C; Barnes R
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S20-5. PubMed ID: 17240252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to interpret a healthcare economic analysis.
    Brown MM; Brown GC
    Curr Opin Ophthalmol; 2005 Jun; 16(3):191-4. PubMed ID: 15870578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which treatment is best for which AMD patient?
    Kroll P; Meyer CH
    Br J Ophthalmol; 2006 Feb; 90(2):128-30. PubMed ID: 16424516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic options in age-related exudative macular degeneration].
    Stanca HT
    Oftalmologia; 2007; 51(1):7-11. PubMed ID: 17605263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The burden of age-related macular degeneration: a value-based analysis.
    Brown MM; Brown GC; Sharma S; Stein JD; Roth Z; Campanella J; Beauchamp GR
    Curr Opin Ophthalmol; 2006 Jun; 17(3):257-66. PubMed ID: 16794438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-related macular degeneration: the costs to society and the patient.
    Gupta OP; Brown GC; Brown MM
    Curr Opin Ophthalmol; 2007 May; 18(3):201-5. PubMed ID: 17435426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-related macular degeneration: an update on treatment.
    Gohel PS; Mandava N; Olson JL; Durairaj VD
    Am J Med; 2008 Apr; 121(4):279-81. PubMed ID: 18374683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polypoidal choroidal vasculopathy and treatments.
    Gomi F; Tano Y
    Curr Opin Ophthalmol; 2008 May; 19(3):208-12. PubMed ID: 18408495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges.
    Schmier JK; Hulme-Lowe CK
    Pharmacoeconomics; 2016 Mar; 34(3):259-72. PubMed ID: 26563248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An introduction to decision analysis in the economic evaluation of the prevention and treatment of vision-related diseases.
    Kymes SM
    Ophthalmic Epidemiol; 2008; 15(2):76-83. PubMed ID: 18432490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value-based medicine and interventions for macular degeneration.
    Brown MM; Brown GC; Brown H
    Curr Opin Ophthalmol; 2007 May; 18(3):194-200. PubMed ID: 17435425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The rapidly evolving diagnosis and treatment of age-related macular degeneration.
    Optometry; 2009 Feb; 80(2):101-6. PubMed ID: 19195112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.